Filling The Rebate Void: PBMs Versus Wholesalers
Executive Summary
The proposal to eliminate rebates in the US raises important follow up questions, including who will be responsible for pharmacy transactions at the point of sale. PBMs say they should stay in that role to assure a smooth transition; independent pharmacies have other ideas.
You may also be interested in...
HHS Rebate Reform: An Air Of Inevitability In Stakeholder Comments
Manufacturers, pharmacy benefit managers and insurers weigh in on the Trump administration’s most significant drug pricing action to date – the HHS Office of Inspector General's proposed rule aimed at eliminating rebates.
PBMs Were On Capitol Hill, But Pharma Still Took Some Heat
Drug makers remained front and center during the Senate Finance Committee's third hearing on drug pricing, even though leaders from five pharmacy benefit managers were testifying.
Is The Opioid REMS Too Big To Study?
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: